Vimian Group ABVIMGF 69 Return-on-Tangible-Asset is 13.46% as of Mar. 2026, which is 202% above its 10-year median of 4.45. GuruFocus rates VIMGF with a GF Score™ of 69/100 and a GF Value™ of $3.19. The stock has 2 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, Vimian Group AB ranks better than 83.64% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Vimian Group AB's annualizedNet Income for the quarter that ended in Mar. 2026 was $45.3 Mil. Vimian Group AB's average total tangible assets for the quarter that ended in Mar. 2026 was $336.6 Mil. Therefore, Vimian Group AB's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 13.46%.
The historical rank and industry rank for Vimian Group AB's Return-on-Tangible-Asset or its related term are showing as below:
VIMGF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -8.47 Med: 4.45 Max: 72.26
Current: 12.28
During the past 9 years, Vimian Group AB's highest Return-on-Tangible-Asset was 72.26%. The lowest was -8.47%. And the median was 4.45%.
VIMGF's Return-on-Tangible-Asset is ranked better than 83.64% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.325
vs VIMGF: 12.28
Vimian Group AB (OTCPK:VIMGF) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Vimian Group AB Return-on-Tangible-Asset Related Terms
Vimian Group AB Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Vimian Group AB's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VIMGF vs TMO, DHR, IDXX: Return-on-Tangible-Asset Comparison
For the Diagnostics & Research subindustry, Vimian Group AB's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vimian Group AB Return-on-Tangible-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Vimian Group AB's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Vimian Group AB's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 13.46% mean?
Vimian Group AB (VIMGF) has a Return-on-Tangible-Asset of 13.46% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Vimian Group AB and its competitors. This is 202% above median its historical median of 4.45. According to the industry distribution chart, Vimian Group AB ranks #35 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 16.4%.
Is Vimian Group AB's Return-on-Tangible-Asset too high?
Vimian Group AB's current Return-on-Tangible-Asset of 13.46% is 202% above median its 10-year median of 4.45. Based on the distribution chart, Vimian Group AB ranks #35 out of 214 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Vimian Group AB has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Vimian Group AB's Return-on-Tangible-Asset compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Vimian Group AB ranks #35 out of 214 companies for Return-on-Tangible-Asset. This places Vimian Group AB in the top 16% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Asset depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Vimian Group AB and its competitors. Vimian Group AB's current Return-on-Tangible-Asset is 13.46%, which is 202% above median its own 10-year median of 4.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vimian Group AB stock overvalued right now?
Vimian Group AB (VIMGF) has a current Return-on-Tangible-Asset of 13.46%. The stock's GF Value™ is $3.19, compared to a current price of $2.77 — trading 13.2% below its estimated fair value. The current Return-on-Tangible-Asset is 13.46%, which is 202% above median its 10-year median of 4.45. Vimian Group AB's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Vimian Group AB (VIMGF), the current Return-on-Tangible-Asset is 13.46% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vimian Group AB (VIMGF) Overvalued in 2026?
Based on GuruFocus' analysis, Vimian Group AB stock appears to be undervalued.
The current stock price of $2.77 is trading 13.2% below its estimated GF Value™ of $3.19.
Key valuation signals for VIMGF:
Return-on-Tangible-Asset: 13.46% (202% above median its 10-year median of 4.45)
GF Value™: $3.19 vs. price of $2.77 (13.2% below fair value)
No single metric tells the full story. See the VIMGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vimian Group AB specializes in the areas of animal health, such as specialty pharma, diagnostics, medtech, and veterinary services. It offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals, with a position within allergy, dermatology, otology, and specialized nutrition. Its geographical segments include Europe, North America, and the Rest of the world.
69GF Score
Get the complete analysis for VIMGF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VIMGF has been successfully added to your 
